Seer : Investor Presentation

Seer Investor Presentation

November 2023

Safe harbor disclosures

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the federal securities laws. These statements relate to future events or Seer, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward- looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "to," "target," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology.

All statements other than statements of historical fact could be deemed forward-looking. These forward-looking statements are subject to a number of risks, uncertainties

and assumptions, including, among other things: any expectations regarding the Company's projections of market opportunities; statements regarding the Company's business strategy, operations, results of operations, financial needs, and financial condition; statements regarding the Company's long-term expectations; statements that may suggest trends for the Company's business or industry, including expectations that may affect the unmet need and the size of the proteomics market and adjacent markets; statements about the Company's collaborations, consortium arrangement, centers of excellence, enablement of future clinical validation, statements about the Company's ability to successfully commercialize the Proteograph™ Product Suite, demand for the Proteograph Product Suite; the launch of any new or additional products, any expectations or statements regarding domestic or global markets, including but not limited to Europe and Asia; statements regarding customer adoption of new technologies domestically and globally; the Company's ability to expand life sciences markets through the use of its technology; the discovery of new protein variants and novel biomarkers leading to therapeutic breakthroughs, the scope of protection the Company is able to successfully establish and maintain for intellectual property rights, including its Proteograph Product Suite, and the number of patents and claims issued, pending or granted; projections, assumptions, and estimates of the Company's future performance, including but not limited to its financial performance, and the future performance of the markets in which it operates; the Company's expectations regarding its gross margins, and operating income and expenses; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, opportunities to drive future growth, and potential markets or market size, or technology developments.​

While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, are described more fully in the Company's filings with the Securities and Exchange Commission ("SEC") and other documents that the Company subsequently files with the SEC from time to time. The Company specifically disclaims any intention to update any forward-looking statements included in this presentation. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of the Company.

2	© 2023 Seer, Inc.

We imagine and pioneer new ways to

decode the secrets of the proteome

to improve human health

3	© 2023 Seer, Inc.

Changing the trajectory

of deep, unbiased proteomics

Enabling customers to	Broadly accessible and
access deep, unbiased,	durably differentiated
rapid proteomics at	technology
scale

Large potential market	Management team
opportunity across	uniquely positioned to
proteomics, genomics	capitalize on proteomics
and new end markets

4

Opening a new frontier in biology

Expanding proteomics and genomics markets via unbiased, deep, and rapid proteomics at scale

5

Sources: Allied Market Research, Technavio

Proteomics

~$24B

© 2023 Seer, Inc.

Unmet need for deep, unbiased proteomics at scale

Academic

Translational

Commercial

Pharma

Applied

Full characterization of the proteome is essential

Static

~20K

Genes

~200K

Transcripts

Transcriptomics

Dynamic

Millions

of Protein Variants

Proteomics

Phenotype

Genomics

Transcription

RNA processing

• >1B genetic variants • Modest correlation of mRNA to proteins
• <0.2% characterized • Distinct expression patterns in different cells

• Protein variants can have distinct function
• Population proteomics will annotate genome variants

Source: Isabell Bludau et al. Proteomic and interactomic insights into the molecular basis of cell functional diversity. Nature Reviews Molecular Cell Biology (2020).

6	© 2023 Seer, Inc.

Functional understanding of protein variants across the population is key

UK Biobank study highlights the unmet need to understand how variation affects function

Population (~455,000 individuals)

Single individual (~20,000 genes)

All protein genetic variants	8,868,971
Potential deleterious variants	6,345,457
Protein loss of function	915,289
Change protein structure/binding	> 3 million

Protein variants per participant	9,506
Potential deleterious variants	2,945
Protein loss of function	214
Alternative splice forms	95% of genes

We have a lot more work to do and we are only at the beginning.

Source: Backman, J.D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628-634 (2021).

7	© 2023 Seer, Inc.

Deep, unbiased proteomics will accelerate our understanding of biology

epr R

o

d

u

			h
		t
		l
	a
	e
	h
	e
v
i
t
c

O	col	y
n	o
			g

Diagnos ti c s

C

o

m p

Genomics

Accelerate functional

characterization of genomic variants

			l
	Proteogenomics		e
s		x
c			d
i			i
t
		s
u
		e
e
		a
p
a		e

r e

h

I

T

n

f

e

e

c

s

t

a

i

o

e

s

u

s

i

d

e

d

r

si

e

a

a

R

s

e

Proteomics

Accelerate discovery of

protein variants

8

Seer is positioned to lead the proteomics revolution

	Empowering
Establishing	at scale, first-of-
Seer as the	their-kind
premier provider	studies
in proteomics
	Making deep,
	unbiased
	proteomics
Enabling unique	accessible to
applications and	more labs
insights

Analyze 10,000 samples per year with 1 Proteograph XT and 1 leading mass spec system

9

Seer enables unbiased,
deep and rapid proteomic
analysis at scale
Unbiased	Deep
Taking advantage of the way proteins interact

A new gateway to the proteome

Lab on a

nanoparticle

Rapid

Large-scale

10	© 2023 Seer, Inc.